0001479290-22-000063.txt : 20220506 0001479290-22-000063.hdr.sgml : 20220506 20220506181936 ACCESSION NUMBER: 0001479290-22-000063 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220504 FILED AS OF DATE: 20220506 DATE AS OF CHANGE: 20220506 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nolet Chris CENTRAL INDEX KEY: 0001782814 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 22902713 MAIL ADDRESS: STREET 1: C/O REVANCE THERAPEUTICS, INC. STREET 2: 7555 GATEWAY BOULEVARD CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wf-form4_165187555569277.xml FORM 4 X0306 4 2022-05-04 0 0001479290 Revance Therapeutics, Inc. RVNC 0001782814 Nolet Chris C/O REVANCE THERAPEUTICS, INC 1222 DEMONBREUN STREET, SUITE 1001 NASHVILLE TN 37203 1 0 0 0 Common Stock 2022-05-04 4 A 0 6059 0 A 25072 D Stock Option (Right to buy) 18.12 2022-05-04 4 A 0 11343 0 A 2032-05-03 Common Stock 11343.0 11343 D Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date. The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy. /s/ Dwight Moxie, Attorney-in-Fact 2022-05-06